Is ImmunityBio (IBRX) a buy or sell right now?
Based on aggregated sentiment from Reddit and News sources, ImmunityBio (IBRX) currently carries an Adanos sell signal with 93/100 conviction. The current cross-source average reads 29% bullish across 2 active sources. Those sources contribute 153 tracked mentions over the last 7 days. This is a sentiment-based reading, not financial advice.
What does Reddit say about IBRX stock?
Reddit discussion around ImmunityBio (IBRX) is moderately active with 111 mentions across 7 tracked subreddits. The tone is 36% bullish with rising momentum, suggesting growing interest over the past week.
What is the sentiment on IBRX stock?
ImmunityBio (IBRX) sentiment is bearish across all 2 tracked sources. Reddit reads 36% bullish, and news coverage is the most negative at 21% bullish. The combined signal points to broad sell-side pressure with 93/100 conviction.
Why does IBRX carry a sell signal right now?
Social sentiment data shows consistently bearish discussion around ImmunityBio (IBRX). All 2 tracked sources lean negative, with news being the most bearish at 21% bullish. Momentum is rising across Reddit and News. The sell signal carries 93/100 conviction.
What is driving ImmunityBio (IBRX) sentiment right now?
Reddit is the dominant discussion channel with 111 mentions (73% of total volume). News contributes 42 mentions. Sentiment is bearish across all sources, but reddit and news momentum is the only one trending upward, which could signal an early shift.
What does the Adanos sell signal mean for ImmunityBio (IBRX)?
The Adanos signal blends bullish ratio, buzz score, source breadth, and 7-day momentum into a single buy/sell reading. IBRX's sell signal at 93/100 conviction reflects consistently bearish sentiment across multiple platforms. It is a research shortcut, not financial advice.
How fresh is this IBRX sentiment data?
The IBRX sentiment page is regenerated from the latest 7-day tracking window at each build. Data reflects the most recent Reddit posts, tweets, and news articles available in the current publishing cycle.